The stock of BeiGene Ltd ADR (BGNE) has gone down by -1.05% for the week, with a 18.17% rise in the past month and a 28.84% rise in the past quarter. The volatility ratio for the week is 2.10%, and the volatility levels for the past 30 days are 3.20% for BGNE. The simple moving average for the last 20 days is 1.89% for BGNE stock, with a simple moving average of 16.61% for the last 200 days.
Is It Worth Investing in BeiGene Ltd ADR (NASDAQ: BGNE) Right Now?
The 36-month beta value for BGNE is also noteworthy at 0.60. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BGNE is 96.14M, and at present, short sellers hold a 2.09% of that float. The average trading volume of BGNE on September 02, 2024 was 256.59K shares.
BGNE) stock’s latest price update
BeiGene Ltd ADR (NASDAQ: BGNE)’s stock price has decreased by -3.39 compared to its previous closing price of 198.50. However, the company has seen a -1.05% decrease in its stock price over the last five trading sessions. zacks.com reported 2024-08-28 that The consensus price target hints at a 27.8% upside potential for BeiGene (BGNE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Analysts’ Opinion of BGNE
Many brokerage firms have already submitted their reports for BGNE stocks, with JP Morgan repeating the rating for BGNE by listing it as a “Overweight.” The predicted price for BGNE in the upcoming period, according to JP Morgan is $185 based on the research report published on February 06, 2024 of the current year 2024.
Macquarie, on the other hand, stated in their research note that they expect to see BGNE reach a price target of $259. The rating they have provided for BGNE stocks is “Outperform” according to the report published on September 12th, 2023.
Jefferies gave a rating of “Buy” to BGNE, setting the target price at $287 in the report published on August 17th of the previous year.
BGNE Trading at 14.73% from the 50-Day Moving Average
After a stumble in the market that brought BGNE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.59% of loss for the given period.
Volatility was left at 3.20%, however, over the last 30 days, the volatility rate increased by 2.10%, as shares surge +17.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +23.30% upper at present.
During the last 5 trading sessions, BGNE fell by -1.05%, which changed the moving average for the period of 200-days by -3.56% in comparison to the 20-day moving average, which settled at $189.65. In addition, BeiGene Ltd ADR saw 6.33% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BGNE starting from PAN-OYLER FOUNDATION, who proposed sale 1,883 shares at the price of $199.22 back on Aug 27 ’24. After this action, PAN-OYLER FOUNDATION now owns shares of BeiGene Ltd ADR, valued at $375,131 using the latest closing price.
Lee Chan Henry, the SVP, General Counsel of BeiGene Ltd ADR, sale 834 shares at $160.57 during a trade that took place back on Jul 30 ’24, which means that Lee Chan Henry is holding 0 shares at $133,915 based on the most recent closing price.
Stock Fundamentals for BGNE
Current profitability levels for the company are sitting at:
- -0.29 for the present operating margin
- 0.83 for the gross margin
The net margin for BeiGene Ltd ADR stands at -0.17. The total capital return value is set at -0.23. Equity return is now at value -14.62, with -9.15 for asset returns.
Based on BeiGene Ltd ADR (BGNE), the company’s capital structure generated 0.24 points at debt to capital in total, while cash flow to debt ratio is standing at -0.67. The debt to equity ratio resting at 0.31. The interest coverage ratio of the stock is -32.66.
Currently, EBITDA for the company is -1.12 billion with net debt to EBITDA at 1.82. When we switch over and look at the enterprise to sales, we see a ratio of 6.46. The receivables turnover for the company is 5.26for trailing twelve months and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.98.
Conclusion
In summary, BeiGene Ltd ADR (BGNE) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
